» Articles » PMID: 34573891

Severe Presentation of Congenital Hemolytic Anemias in the Neonatal Age: Diagnostic and Therapeutic Issues

Overview
Specialty Radiology
Date 2021 Sep 28
PMID 34573891
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital hemolytic anemias (CHAs) are a group of diseases characterized by premature destruction of erythrocytes as a consequence of intrinsic red blood cells abnormalities. Suggestive features of CHAs are anemia and hemolysis, with high reticulocyte count, unconjugated hyperbilirubinemia, increased lactate dehydrogenase (LDH), and reduced haptoglobin. The peripheral blood smear can help the differential diagnosis. In this review, we discuss the clinical management of severe CHAs presenting early on in the neonatal period. Appropriate knowledge and a high index of suspicion are crucial for a timely differential diagnosis and management. Here, we provide an overview of the most common conditions, such as glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase deficiency, and hereditary spherocytosis. Although rare, congenital dyserythropoietic anemias are included as they may be suspected in early life, while hemoglobinopathies will not be discussed, as they usually manifest at a later age, when fetal hemoglobin (HbF) is replaced by the adult form (HbA).

Citing Articles

Risk of low levels of blood group antibodies mediating hemolysis in ABO-incompatible neonates with negative three hemolysis tests.

Lin H, Luo P, Liu C, Lin X, Que C, Zhong W Front Pediatr. 2024; 12:1392308.

PMID: 39161638 PMC: 11330777. DOI: 10.3389/fped.2024.1392308.


Current Status of Molecular Diagnosis of Hereditary Hemolytic Anemia in Korea.

Chueh H, Shim Y, Jung H, Kim N, Hwang S, Kim M J Korean Med Sci. 2024; 39(18):e162.

PMID: 38742293 PMC: 11091231. DOI: 10.3346/jkms.2024.39.e162.


Clinical value of combined predictors of RET%, γ-GT, LDH in the ABO neonatal hemolytic disease.

Liu X, Dong Y, Qin Y, Xue C, Lyu W Front Pediatr. 2023; 11:1265739.

PMID: 38105791 PMC: 10725244. DOI: 10.3389/fped.2023.1265739.


The application value of mean red blood cell volume and red blood cell volume distribution width combined with total serum bilirubin in the early screening of neonatal hemolytic disease.

Lin H, Luo P, Liu C, Lin X, Que C, Zhong W BMC Pediatr. 2023; 23(1):19.

PMID: 36639749 PMC: 9837968. DOI: 10.1186/s12887-022-03812-2.


Korean clinical practice guidelines for the diagnosis of hereditary hemolytic anemia.

Chueh H, Hwang S, Shim Y, Lee J, Park H, Lee J Blood Res. 2022; 57(2):86-94.

PMID: 35593002 PMC: 9242826. DOI: 10.5045/br.2022.2021224.


References
1.
Liu H, Liu W, Tang X, Wang T . Association between G6PD deficiency and hyperbilirubinemia in neonates: a meta-analysis. Pediatr Hematol Oncol. 2014; 32(2):92-8. DOI: 10.3109/08880018.2014.887803. View

2.
Secrest M, Storm M, Carrington C, Casso D, Gilroy K, Pladson L . Prevalence of pyruvate kinase deficiency: A systematic literature review. Eur J Haematol. 2020; 105(2):173-184. PMC: 7496626. DOI: 10.1111/ejh.13424. View

3.
Kaplan M, Muraca M, Hammerman C, Rubaltelli F, Vilei M, Vreman H . Imbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics. 2002; 110(4):e47. DOI: 10.1542/peds.110.4.e47. View

4.
Rab M, van Oirschot B, Kosinski P, Hixon J, Johnson K, Chubukov V . AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2020; 106(1):238-249. PMC: 7776327. DOI: 10.3324/haematol.2019.238865. View

5.
Lauer B, Spector N . Hyperbilirubinemia in the newborn. Pediatr Rev. 2011; 32(8):341-9. DOI: 10.1542/pir.32-8-341. View